Regulus Therapeutics (RGLS) Upgraded by Zacks Investment Research to Buy
Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a $1.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 11.11% from the company’s current price.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
A number of other research analysts have also weighed in on the company. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a report on Tuesday, January 16th. Leerink Swann began coverage on Regulus Therapeutics in a report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.50.
Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.18). Regulus Therapeutics had a negative return on equity of 189.71% and a negative net margin of 107,606.96%. research analysts expect that Regulus Therapeutics will post -1.03 EPS for the current year.
A number of institutional investors have recently modified their holdings of RGLS. Quantitative Investment Management LLC purchased a new position in shares of Regulus Therapeutics in the second quarter valued at $103,000. GSA Capital Partners LLP purchased a new position in Regulus Therapeutics during the second quarter worth about $139,000. Royal Bank of Canada grew its position in Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 19,934 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Regulus Therapeutics during the third quarter worth about $347,000. Finally, Goldman Sachs Group Inc. grew its position in Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after buying an additional 240,890 shares in the last quarter. Institutional investors and hedge funds own 59.39% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.